title: BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
abstract: OBJECTIVE
  The HD9 trial aims to evaluate whether moderate dose escalation and/or acceleration of standard polychemotherapy is beneficial for advanced-stage Hodgkin's disease (HD). Two variants of a novel bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) scheme (standard and escalated dose) are compared with cyclophosphamide, vincristine, procarbazine, and prednisone (COPP)/doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).
  
  
  METHODS
  The randomized, three-arm trial recruited patients in stages IIB and IIIA with risk factors and stages IIIB and IV. BEACOPP in baseline dose contains all drug dosages of COPP/ABVD (except vincristine and procarbazine) rearranged in a shorter, 3-week cycle. Escalated BEACOPP uses higher doses of cyclophosphamide, doxorubicin, and etoposide with granulocyte colony-stimulating factor (G-CSF) support. After eight chemotherapy cycles, initial bulky and residual disease is irradiated. The trial is monitored and analyzed by means of a sequential strategy.
  
  
  RESULTS
  An interim analysis with 505 assessable patients and a median follow-up of 23 months showed a significant inferiority (according to sequential monitoring strategy) of the COPP/ABVD regimen in progression rate and freedom from treatment failure (FFTF) compared with the pooled results of both BEACOPP variants. The 24-month FFTF rate was 75% for COPP/ABVD and 84% for BEACOPP pooled (P = .034). There was 12% progressive disease with COPP/ABVD and 6% with BEACOPP pooled. Differences in survival were not significant in sequential analysis. The acute toxicity of baseline BEACOPP resembled that of COPP/ABVD; escalated BEACOPP showed increased but manageable hematologic toxicity.
  
  
  CONCLUSIONS
  Combined with local irradiation, BEACOPP in one or both variants shows superior disease control compared with COPP/ABVD, with acceptable acute toxicity. Further follow-up is required to assess the effect of dosage and the effect on survival and late toxicities.
authors.affiliation: Department of Internal Medicine, University of Cologne, Germany. v.diehl@uni-koeln.de
authors.forename: V
authors.initials: V
authors.lastname: Diehl
authors.forename: J
authors.initials: J
authors.lastname: Franklin
authors.forename: D
authors.initials: D
authors.lastname: Hasenclever
authors.forename: H
authors.initials: H
authors.lastname: Tesch
authors.forename: M
authors.initials: M
authors.lastname: Pfreundschuh
authors.forename: B
authors.initials: B
authors.lastname: Lathan
authors.forename: U
authors.initials: U
authors.lastname: Paulus
authors.forename: M
authors.initials: M
authors.lastname: Sieber
authors.forename: J U
authors.initials: JU
authors.lastname: Rueffer
authors.forename: M
authors.initials: M
authors.lastname: Sextro
authors.forename: A
authors.initials: A
authors.lastname: Engert
authors.forename: J
authors.initials: J
authors.lastname: Wolf
authors.forename: R
authors.initials: R
authors.lastname: Hermann
authors.forename: L
authors.initials: L
authors.lastname: Holmer
authors.forename: U
authors.initials: U
authors.lastname: Stappert-Jahn
authors.forename: E
authors.initials: E
authors.lastname: Winnerlein-Trump
authors.forename: G
authors.initials: G
authors.lastname: Wulf
authors.forename: S
authors.initials: S
authors.lastname: Krause
authors.forename: A
authors.initials: A
authors.lastname: Glunz
authors.forename: K
authors.initials: K
authors.lastname: von Kalle
authors.forename: H
authors.initials: H
authors.lastname: Bischoff
authors.forename: C
authors.initials: C
authors.lastname: Haedicke
authors.forename: E
authors.initials: E
authors.lastname: Duehmke
authors.forename: A
authors.initials: A
authors.lastname: Georgii
authors.forename: M
authors.initials: M
authors.lastname: Loeffler
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001317:Austria; D001761:Bleomycin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D018153:Czech Republic; D003606:Dacarbazine / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005858:Germany; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D013557:Switzerland; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D005047:Etoposide; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone